Full Biospring Team

Dr. David Mauney

Former Managing Director, Koch Disruptive Technologies

David is a Senior Advisor at Biospring Partners where he works closely with the investment team across the pharma services sector. He brings nearly 30 years of experience spanning healthcare operations and investing. He has served in governance roles across the ecosystem: as a general partner (GP), limited partner (LP), and a limited partner advisory committee (LPAC) member. He has also served on investment committees and as a member of the Board of Directors.

Prior to joining Biospring, David was a Managing Director at Koch Disruptive Technologies, where he led the healthcare investment strategy across multiple subsectors, overseeing a substantial private investment portfolio. Earlier in his career, David held senior leadership roles at several healthcare firms and co-founded two healthcare investment firms. David holds a BA from Duke University and an MD from Geisel School of Medicine at Dartmouth.

Other Advisory Board Members

  • Dr. Moncef Slaoui

    Dr. Moncef Slaoui

    Former Chairman of Pharma R&D, Chairman Global R&D, Vaccines & Oncology, GSK; Operation Warp Speed

  • Sir John Bell

    Sir John Bell

    Regius Professor of Medicine at Oxford University

  • David Final

    Dr. David Mauney

    Former Managing Director, Koch Disruptive Technologies

  • Dr. John Baldoni

    Dr. John Baldoni

    Board Director & Advisor

  • Bob Pozen

    Bob Pozen

    Senior Fellow at the Brookings Institution

  • Qi Wang

    Qi Wang

    CIO, Portfolio Implementation, PIMCO

  • Dr. Peter Henry

    Dr. Peter Henry

    Senior Fellow, Hoover Institution

  • Dr. John Sexton

    Dr. John Sexton

    President Emeritus, New York University